scholarly journals Testicular Cancer Survivorship

2019 ◽  
Vol 17 (12) ◽  
pp. 1557-1568 ◽  
Author(s):  
Chunkit Fung ◽  
Paul C. Dinh ◽  
Sophie D. Fossa ◽  
Lois B. Travis
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivorship ◽  
Relative Survival ◽  
Future Research ◽  
Malignant Neoplasms ◽  
Long Term Effects ◽  
Long Term Treatment ◽  
Second Malignant Neoplasms

Testicular cancer (TC) is the most common cancer among men aged 18 to 39 years. It is highly curable, with a 10-year relative survival approaching 95% due to effective cisplatin-based chemotherapy. Given the increasing incidence of TC and improved survival, TC survivors (TCS) now account for approximately 4% of all US male cancer survivors. They have also become a valuable cohort for adult-onset cancer survivorship research, given their prolonged survival. Commensurately, long-term treatment-related complications have emerged as important survivorship issues. These late effects include life-threatening conditions, such as second malignant neoplasms and cardiovascular disease. Moreover, TCS can also experience hearing loss, tinnitus, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, infertility, anxiety, depression, cognitive impairment, and chronic cancer-related fatigue. Characterization of the number and severity of long-term adverse health outcomes among TCS remains critical to develop risk-stratified, evidence-based follow-up guidelines and to inform the development of preventive measures and interventions. In addition, an improved understanding of the long-term effects of TC treatment on mortality due to noncancer causes and second malignant neoplasms remains paramount. Future research should focus on the continued development of large, well-characterized clinical cohorts of TCS for lifelong follow-up. These systematic, comprehensive approaches can provide the needed infrastructure for further investigation of long-term latency patterns of various medical and psychosocial morbidities and for more in-depth studies investigating associated etiopathogenetic pathways. Studies examining premature physiologic aging may also serve as new frontiers in TC survivorship research.

Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular Cancer

2007 ◽  
Vol 25 (28) ◽  
pp. 4370-4378 ◽  
Author(s):  
Alexandra W. van den Belt-Dusebout ◽  
Ronald de Wit ◽  
Jourik A. Gietema ◽  
Simon Horenblas ◽  
Marieke W.J. Louwman ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cox Regression ◽  
Late Complication ◽  
Late Complications ◽  
Malignant Neoplasms ◽  
Second Malignancies ◽  
Similar Extent ◽  
Second Malignant Neoplasms

Purpose To compare radiotherapy and chemotherapy effects on long-term risks of second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs) in testicular cancer (TC) survivors. Patients and Methods In our nationwide cohort comprising 2,707 5-year TC survivors, incidences of SMNs and CVDs were compared with general-population rates by calculating standardized incidence ratios (SIRs) and absolute excess risks (AERs). Treatment effects on risks of SMN and CVD were quantified in multivariable Cox regression and competing risks analyses. Results After a median follow-up time of 17.6 years, 270 TC survivors developed SMNs. The SIR of SMN overall was 1.7 (95% CI, 1.5 to 1.9), with an AER of 32.3 excess occurrences per 10,000 person-years. SMN risk was 2.6-fold (95% CI, 1.7- to 4.0-fold) increased after subdiaphragmatic radiotherapy and 2.1-fold (95% CI, 1.4- to 3.1-fold) increased after chemotherapy, compared with surgery only. Subdiaphragmatic radiotherapy increased the risk of a major late complication (SMN or CVD) 1.8-fold (95% CI, 1.3- to 2.4-fold), chemotherapy increased the risk of a major late complication 1.9-fold (95% CI, 1.4- to 2.5-fold), and smoking increased the risk of a major late complication 1.7-fold (95% CI, 1.4- to 2.1-fold), compared with surgery only. The median survival time was 1.4 years after SMN and 4.7 years after CVD. Conclusion Radiotherapy and chemotherapy increased the risk of developing SMN or CVD to a similar extent as smoking. Subdiaphragmatic radiotherapy strongly increases the risk of SMNs but not of CVD, whereas chemotherapy increases the risks of both SMNs and CVDs. Prolonged follow-up after chemotherapy is needed to reliably compare the late complications of radiotherapy and chemotherapy after 20 years.

scholarly journals Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer

1997 ◽  
Vol 89 (19) ◽  
pp. 1429-1439 ◽  
Author(s):  
L. B. Travis ◽  
R. E. Curtis ◽  
J. F. Fraumeni ◽  
J. D. Boice ◽  
H. Storm ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Malignant Neoplasms ◽  
Second Malignant Neoplasms ◽  
Long Term Survivors

Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9007-9007
Author(s):  
R. Goldsby ◽  
C. Burke ◽  
R. Nagarajan ◽  
T. Zhou ◽  
Z. Chen ◽  
...  
Keyword(s):  
Bone Tumors ◽  
Univariate Analysis ◽  
Primary Diagnosis ◽  
Malignant Neoplasms ◽  
Solid Organ ◽  
Malignant Bone Tumors ◽  
Entire Cohort ◽  
Second Malignant Neoplasms

9007 Background: The growing number of individuals surviving childhood cancer has increased the awareness and recognition of long-term sequelae. One of the most worrisome complications following cancer therapy is the development of second malignant neoplasms (SMN), in particular, late-occurring solid second malignancies related radiation therapy. Methods: We describe the incidence of solid organ SMN in survivors of pediatric malignant bone tumors (MBT) treated on legacy CCG/POG protocols from 1980 to 2005. This retrospective cohort study included 2,842 patients, 1,686 treated for osteosarcoma (OS) and 1,156 treated for Ewings Sarcoma (ES). The cohort included 56% males and 44% females, with a median age at primary diagnosis of 13 years. The median length of follow-up was 4.3 years (range: 0 to 20.9 years). Results: At the time of the analysis, 64% of patients in this study are alive. Seventeen patients with solid organ SMN were identified, and included three patients with breast cancer, three with malignant fibrous histiocytoma, two with osteosarcoma, and 9 patients with other solid organ malignancies. The standardized incidence ratio (SIR=observed/expected cases) was 2.9 (95% confidence interval [CI], 1.4–5.4) for patients treated for OS and 5.0 (95%CI 2.6–9.4) for patients treated for ES. The median time from diagnosis to develop solid organ SMN was 7 years (range: 1 to 13 years). The 10-year cumulative incidence of solid organ SMN for the entire cohort was 1% (95%CI 0.6–2%). In univariate analysis, treatment with etoposide, cyclophosphamide or radiotherapy were each associated with a higher than expected incidence of cancer with SIR of 4.8 (95% CI, 2.5–9.5), 5.8 (95% CI, 3.5–9.5) and 4.1 (95% CI, 2.4–7.1), respectively. Conclusions: Solid organ SMNs are rare after treatment for OS and ES, although higher in patients treated for ES. Recurrence remains the most significant problem for patients diagnosed with MBT and development of improved therapies with fewer long-term consequences remains paramount. However, solid organ cancers are likely to increase with longer follow-up. Therefore, surveillance should focus on monitoring for both recurrence of primary malignancies and development of SMN. No significant financial relationships to disclose.

scholarly journals Secondary T-cell lymphoblastic lymphoma in a child after anticancer therapy for neuroblastoma: clinical case

2020 ◽  
Vol 7 (2) ◽  
pp. 115-119
Author(s):  
Yu. K. Toshina ◽  
Yu. V. Dinikina ◽  
A. S. Egorov ◽  
A. Yu. Smirnova ◽  
M. B. Belogurova
Keyword(s):  
T Cell ◽  
Clinical Case ◽  
Lymphoblastic Leukemia ◽  
Malignant Neoplasms ◽  
Long Term Effects ◽  
Antitumor Therapy ◽  
Second Malignant Neoplasms ◽  
Anticancer Treatment ◽  
One Year

Neuroblastoma (NB) is the most common extra-cranial solid tumor in infants with the most heterogeneous clinical course to compare with other malignant diseases. Due to intensive multimodal anticancer treatment there are an increased number of survivors and issues related to long-term effects are becoming increasingly important. One of them is the risk of secondary malignant neoplasms. This article represents a clinical case of T-cell lymphoblastic leukemia in a child aged 2 years and 5 months who received combined antitumor therapy for NB with an intermediate risk group under the age of one year. We observed literature data to investigate the incidence of second malignant neoplasms in patients with NB for the period from 1948 to 2018 and analyzed risk factors.

Sopravvivere al cancro: una rassegna sulla Qualitŕ di Vita nella cancer survivorship

2009 ◽  
pp. 55-71
Author(s):  
Maria Antonietta Anunziata ◽  
Barbara Muzzatti ◽  
Katia Bianchet ◽  
Massimiliano Berretta ◽  
Emanuela Chimienti ◽  
...  
Keyword(s):  
Cancer Survivorship ◽  
Perceived Social Support ◽  
Future Research ◽  
Long Term Effects ◽  
Point Model ◽  
Medical Progress ◽  
Definition Of ◽  
Practical Implications

- Thanks to substantial medical progress, today the number of cancer survivors constantly increases. Thus, ever more frequently, patients and healthy professionals must treat a new condition: the cancer survivorship. This condition is peculiar for both its somatic (e.g. the late and long term effects of the treatments) and psychosocial (e.g. psychological distress, fear for a relapse, perceived social support) implications. The present paper is a review of the recent international literature about cancer survivorship; a condition still less known in Italy. First the definition of cancer survivorship is discussed and then cancer survivorship is addressed through a four point model of the concept of Quality of Life. In the last section, the authors will examine the expectation for future research, as well as the possible limitations, together with the practical implications of this topic.

scholarly journals Assessing the influence of special treatment of differentiated thyroid cancer on the urinary system long-term effects

2021 ◽  
Vol 29 (3) ◽  
pp. 22-30
Author(s):  
L.Ya. Vasyliev ◽  
Ye.B. Radzishevska ◽  
A.S. Savchenko ◽  
H.V. Kulinich ◽  
O.O. Solodovnikova
Keyword(s):  
Thyroid Cancer ◽  
Hormone Therapy ◽  
Differentiated Thyroid Cancer ◽  
Special Treatment ◽  
Malignant Neoplasms ◽  
Urinary System ◽  
Long Term Effects ◽  
Long Term Consequences

Background. Differentiated thyroid cancer (DTC) is the most common endocrine tumour. Its prevalence varies from 1.0% to 2.2% of all malignant neoplasms. The standard strategy of special treatment of DTC consists of surgery, radionuclide therapy and hormone therapy being sequentially applied. Theoretically, each component of the treatment process can cause adverse somatic consequences in future, the study of which can help to prevent and correct them. Purpose – to evaluate possible long-term effects of the treatment of differentiated thyroid cancer in the form of the urinary system (US) pathologies on the basis of follow-up data of long-term observation using sophisticated information technologies. Materials and methods. The study was based on follow-up data of 157 individuals who were undergoing combination treatment of DTC at the Institute clinic from 1993 to 2015, received it in full and underwent regular screening examinations after treatment. The database created for the study contained, as much as possible, digitized arrays of follow-up data of paper case-records on the disease and its consequences in patients with a follow-up period exceeding 1 year after special treatment. The number of logical records of long-term consequences in the generated database was 463 units – one record for one type of long-term consequences of each of 157 patients. Statistical processing of data was carried out in two ways: comparing the incidence of US pathologies before treatment and at a long time after special treatment and identifying factors of statistically significant influence on the occurrence of US pathologies among the treatment peculiarities. WizWhy packages (Data Mining category) and the general purpose software package STATISTICA were used to make hypotheses and test them. Results and discussion. The analysis of the available references has shown that there is only a limited number of papers dealing with the US status of DTC patients. However, a comprehensive analysis of the long-term consequences of treatment of DTC patients revealed a statistically significant increase of US disease cases within the period of 3.75 – 4.8 years after special treatment. It was shown that the total number of US pathologies was 2.04 times higher in comparison with US incidence before the oncet of special treatment. These differences did not depend on age: the median for age of patients before treatment was 51 years, after treatment – 50 years. Additionally, it has been found that patients with or without episodes of postoperative hypothyroidism decompensation with a dose of L-thyroxine not exceeding 2.5 μg/kg need special attention due to the occurrence of urolithiasis. The obtained dependences are quite predictable, since, firstly, it is known that thyroid hormones affect kidney development and physiology, and secondly, the major percent of 131I in radioiodine therapy is excreted with the urine and deposited in the bladder, that can result in a radio-induced carcinogenic effect. Conclusions. Special treatment of DTC increases US pathologies more than twice. The term of post-treatment pathologies is 2.5 (3.75 – 4.8) years. Patients who have episodes of postoperative hypothyroidism during hormone therapy with a dose of L-thyroxine not exceeding 2.5 μg / kg represent the high-risk group.

Methodological Considerations for Auditory Training Interventions for Adults With Hearing Loss: A Rapid Review

2021 ◽  
Vol 30 (1) ◽  
pp. 211-225
Author(s):  
Laura Gaeta ◽  
Rachel Keiko Stark ◽  
Erika Ofili
Keyword(s):  
Hearing Loss ◽  
Outcome Measures ◽  
Auditory Training ◽  
Rapid Review ◽  
Future Research ◽  
Control Group ◽  
Long Term Effects ◽  
Training Interventions

Purpose The aim of this study was to evaluate literature on auditory training published since 2013. Method A rapid review or a streamlined approach to systematically identify and summarize relevant studies was performed. Selected health sciences databases were searched using a search strategy developed with the PICO (population, intervention, comparison, and outcome) framework. Studies eligible for inclusion had older adult participants with hearing loss and utilized technology-based auditory training in laboratory or home settings. Results The study quality of most studies was found to be low to moderate, with concentrations between low and moderate. Major issues were related to study design and reporting, such as the need for blinding and a control group, larger sample sizes, and a follow-up for long-term outcomes of auditory training interventions. Wide variability in training approaches, participant backgrounds (e.g., audiograms, hearing aid use), and outcome measures are also noted. Conclusions Evidence on the effectiveness of auditory training is mixed. Future research should include high-quality randomized controlled trials with representative populations; follow-up periods to study long-term effects; and exploration of behavioral, electrophysiological, and self-reported outcome measures. Recommendations for study designs and methodologies are also discussed.

Long-term effects of chemotherapy in patients with testicular cancer.

1992 ◽  
Vol 10 (4) ◽  
pp. 574-579 ◽  
Author(s):  
S Osanto ◽  
A Bukman ◽  
F Van Hoek ◽  
P J Sterk ◽  
J A De Laat ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Germ Cell Tumors ◽  
Conversational Speech ◽  
Long Term Effects ◽  
Long Term Effect ◽  
Hearing Function ◽  
Testicular Carcinoma ◽  
The Individual

PURPOSE Combination chemotherapy regimens that include cisplatin (CDDP) and bleomycin (BLE) result in the cure of the majority of patients with malignant germ cell tumors of the testis. We investigated the long-term damage of such chemotherapy to renal, pulmonary, and hearing function. PATIENTS AND METHODS Forty-three patients with disseminated testicular carcinoma were studied 1.5 to 9.3 years (median, 4.1 years) after completion of chemotherapy. All 43 patients received CDDP; of these, 39 also received BLE, 27 vinblastine (VLB), and 27 etoposide (VP-16). Mean cumulative doses of individual cytotoxic drugs administered were CDDP 483 mg/m2 (range, 189 to 1,173 mg/m2), BLE 160 mg/m2 (range, 81 to 311 mg/m2), VLB 31 mg/m2 (range, 19 to 158 mg/m2), and VP-16 667 mg/m2 (range, 242 to 1,455 mg/m2). RESULTS In the majority of cases, values of renal, pulmonary, and hearing function were within the normal range before treatment. An initial decrease in renal, pulmonary, and hearing function was observed, with recovery of pulmonary function at late follow-up. On average, a decrease of 15% in creatinine clearance rates was observed at late follow-up. Long-term effect on audiometric function was considerable, but frequencies affected were outside the range of conversational speech. With multivariate analysis, no overall relation between the cumulative doses of the individual drugs and the loss in organ function was found; the cumulative doses of CDDP and BLE only contributed approximately 30% to the loss in renal function and vital capacity, respectively. CONCLUSION Chemotherapy-induced pulmonary toxicity is reversible, whereas nephrotoxicity and ototoxicity are not. However, the long-term effects of chemotherapy in testicular cancer patients were minor and not invalidating.

Long-Term and Late Effects of Germ Cell Testicular Cancer Treatment and Implications for Follow-Up

2012 ◽  
Vol 30 (30) ◽  
pp. 3752-3763 ◽  
Author(s):  
Hege S. Haugnes ◽  
George J. Bosl ◽  
Hink Boer ◽  
Jourik A. Gietema ◽  
Marianne Brydøy ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Testicular Cancer ◽  
Germ Cell ◽  
Late Effects ◽  
Current Status ◽  
Malignant Neoplasms ◽  
Treatment Type ◽  
Increased Risk

Germ cell testicular cancer (TC) represents a malignancy with high cure rates. Since the introduction of cisplatin-based chemotherapy in the late 1970s, the 5-year survival rate has increased considerably, and it is currently above 95%. Because TC is usually diagnosed before the age of 40 years, these men can expect to live for another 40 to 50 years after being successfully treated. This success, however, is hampered by an increased risk of long-term and late effects of treatment. Secondary malignant neoplasms and cardiovascular disease represent the most common potentially life-threatening late effects, typically occurring more than 10 years after treatment. Other long-term effects include pulmonary toxicity, nephrotoxicity, neurotoxicity, decreased fertility, hypogonadism, and psychosocial problems. The incidence and time to onset of these various adverse effects vary according to treatment type and intensity. There is still little knowledge about underlying mechanisms and genetic susceptibility of the various adverse effects. Apart from treatment burden, it is not yet possible to identify patients who are at high risk for certain late effects after TC treatment. In this clinical review, we present the current status regarding different somatic and psychosocial long-term late effects after treatment for TC, based on Medline searches and our own research. Moreover, we postulate recommendations for general medical evaluations that should begin after treatment is completed and continue during follow-up.

Sign in / Sign up

Export Citation Format

Share Document